Merus BV focuses on next generation therapeutic human monoclonal antibodies including bispecific antibodies and mixtures of antibodies (Oligoclonics TM). We have developed two technology platforms that constitute the basis for these innovative antibody formats.
- A transgenic mouse for the generation of human monoclonal antibodies (MeMo TM) with a single light chain. Human monoclonal antibody repertoires from these mice can be directly screened in the relevant therapeutic format and have built-in desirable development and manufacturing features.
- Screening and expression technologies to efficiently mine the entire antibody repertoire produced by MeMo TM upon immunisation and to rapidly identify lead candidates by functional screening of the relevant antibody format.
Merus’ products pipeline comprises bispecific antibodies and oligoclonics for application in oncology, infectious diseases and chronic inflammatory diseases.